

Astrid Wiens

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9317066/astrid-wiens-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

428
citations

12
h-index

20
g-index

35
ext. papers

540
ext. citations

3.5
avg, IF

3.51
L-index

#	Paper	IF	Citations
31	Cost-Effectiveness of Molecular Method Diagnostic for Rapid Detection of Antibiotic-Resistant Bacteria. <i>Value in Health Regional Issues</i> , 2021 , 27, 12-20	1.6	
30	Solid Oral Dosage Forms Use in Adults with Neurological Disorders and Swallowing Difficulties: A Scoping Review. <i>Dysphagia</i> , 2021 , 1	3.7	0
29	Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 735-740	4.1	
28	Diagnosis and prediction of COVID-19 severity: can biochemical tests and machine learning be used as prognostic indicators?. <i>Computers in Biology and Medicine</i> , 2021 , 134, 104531	7	12
27	Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review. <i>PLoS ONE</i> , 2020 , 15, e0231722	3.7	2
26	Evaluation of the application of the Diabetes Quality of Life Questionnaire in patients with diabetes mellitus. <i>Archives of Endocrinology and Metabolism</i> , 2020 , 64, 59-65	2.2	4
25	Vitamins, antioxidants, and type 2 diabetes 2020 , 373-383		1
24	Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102435	4	3
23	Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials: a scoping review protocol. <i>JBI Evidence Synthesis</i> , 2020 , 18, 1781-1787	2.1	3
22	Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. <i>Value in Health Regional Issues</i> , 2019 , 20, 95-102	1.6	0
21	Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 7-15	4	7
20	Description of network meta-analysis geometry: A metrics design study. <i>PLoS ONE</i> , 2019 , 14, e0212650	3.7	12
19	DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2018 , 34, 180-188	1.8	7
18	Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Diabetology and Metabolic Syndrome</i> , 2018 , 10, 18	5.6	39
17	Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. <i>CNS Drugs</i> , 2018 , 32, 813-826	6.7	34
16	Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1513-1521	2.8	2
15	Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). <i>BioDrugs</i> , 2018 , 32, 377-390	7.9	5

14	Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. <i>Mycoses</i> , 2018 , 61, 754-763	5.2	13
13	Cost effectiveness of dressing in the prevention of catheter-related infection in critically ill patients. <i>Journal of Infection in Developing Countries</i> , 2018 , 12, 871-877	2.3	1
12	Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1672-1683	4.8	28
11	Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 749-755	4	9
10	Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1-14	2.8	10
9	Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. <i>Mycoses</i> , 2017 , 60, 146-154	5.2	37
8	Update on Biologic Therapies for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2016 , 18, 44	4.9	9
7	Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2016 , 11, 49-61	4.9	17
6	Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis. <i>Schizophrenia Research</i> , 2015 , 169, 483-485	3.6	4
5	Impact of Natural Juice Consumption on Plasma Antioxidant Status: A Systematic Review and Meta-Analysis. <i>Molecules</i> , 2015 , 20, 22146-56	4.8	20
4	Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. <i>Pharmacotherapy</i> , 2013 , 33, 144-51	5.8	15
3	A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. <i>Rheumatology International</i> , 2010 , 30, 1063-70	3.6	29
2	Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> , 2010 , 30, 339-53	5.8	82
1	A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. <i>Scandinavian Journal of Immunology</i> , 2009 , 70, 337-44	3.4	23